Cargando…

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD), or are in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Jonas, Mares, Jan, Barnett, Michael, Aktas, Orhan, Albrecht, Philipp, Zamvil, Scott S., Hartung, Hans-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Views & Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063619/ https://www.ncbi.nlm.nih.gov/pubmed/33406479 http://dx.doi.org/10.1212/NXI.0000000000000918

Ejemplares similares

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) und Anti-Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankungen (MOGAD)
por: Seifert-Held, Thomas
Publicado: (2022)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
por: Contentti, Edgar Carnero, et al.
Publicado: (2021)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Neuroprotective Properties of 4-Aminopyridine
por: Dietrich, Michael, et al.
Publicado: (2021)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?
por: Zamvil, Scott S., et al.
Publicado: (2015)

Restoring immune tolerance in neuromyelitis optica: Part I
por: Steinman, Larry, et al.
Publicado: (2016)

Restoring immune tolerance in neuromyelitis optica: Part II
por: Bar-Or, Amit, et al.
Publicado: (2016)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode
por: Pakeerathan, T., et al.
Publicado: (2022)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS
por: Aktas, Orhan, et al.
Publicado: (2020)

COVID-19 in MS and NMOSD: A multicentric online national survey in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
por: Esmaeili, Sara, et al.
Publicado: (2021)

To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection
por: Stastna, Dominika, et al.
Publicado: (2022)

Clinical and neuroimaging findings in MOGAD–MRI and OCT
por: Bartels, Frederik, et al.
Publicado: (2021)

Attack phenotypes and disease course in pediatric MOGAD
por: Santoro, Jonathan D., et al.
Publicado: (2023)

Editorial: MOGAD, current knowledge and future trends
por: Siritho, Sasitorn, et al.
Publicado: (2023)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients
por: Lee, John-Ih, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8255f8uil7rgqic1j0uol7fcs7